# Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)

> **NCT06463457** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Atish Choudhury, MD** · enrollment: 33 (estimated)

## Conditions studied

- Prostate Cancer
- Advanced Prostate Cancer
- Hormone Sensitive Prostate Cancer

## Interventions

- **DRUG:** Darolutamide
- **DRUG:** Relugolix

## Key facts

- **NCT ID:** NCT06463457
- **Lead sponsor:** Atish Choudhury, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-13
- **Primary completion:** 2028-11-30
- **Final completion:** 2028-11-30
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-03-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06463457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06463457, "Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06463457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*